Oncología (médica)

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estatus, etc.

1. A Study to Explore the Mechanisms that Separate Responders Versus Non-responders to Treatment such as Immunotherapy, Target Therapy and Chemotherapy in Lung Cancer Patients

   Jacksonville, Fla.

   The purpose of this study is to explore the underlying mechanisms that distinguishes responder versus non-responders to treatment such as immunotherapy, target therapy and chemotherapy in lung cancer and mechanisms of resistance. The information generated from this study will likely help to design the optimal strategies to improve clinical outcomes in lung cancers.

2. Blood and Urine Identification of Methylated DNA Markers in Invasive Bladder Carcinoma

   Rochester, Minn.

   The purpose of this study is to, in tissue, discover and validate DNA methylation markers (MDMs) for detection of invasive urothelial carcinoma of the bladder. In blood, to assess the accuracy of candidate MDMs from above for detection of invasive urothelial carcinoma of the bladder. In urine, to explore the accuracy of candidate MDMs from above for detection of invasive urothelial carcinoma of the bladder.  Diagnostic accuracy on urine can be compared with that on plasma using paired samples.

3. Screening for High Frequency Malignant Disease

   Rochester, Minn., La Crosse, Wis., Eau Claire, Wis.

   The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.

    

4. A Study to Evaluate DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study

   Rochester, Minn.

   The purpose of this study is train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features. 

5. TheraSphere With and Without Durvalumab and Tremelimumab for HCC

   Jacksonville, Fla.

   The objective of the ROWAN clinical study is to assess the the durability of local tumor control in Hepatocellular Carcinoma (HCC) patients who receive TheraSphere followed by durvalumab and tremelimumab, compared to those who receive TheraSphere treatment alone.

6. Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors

   Rochester, Minn.

   The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of mutations associated solid tumors.

   The performance characteristics of these assays for detecting ctDNA mutation in oncology patients will be assessed by comparing the mutation results obtained from these assays to those obtained by orthogonal methods, including tissue-based assays and results from a ctDNA assay by Guardant on blood.

7. A Study to Evaluate the Effectiveness and Safety of Remdesivir to Treat Coronavirus Disease 2019 in an Outpatient Setting

   Rochester, Minn.

   The purpose of this study is to evaluate the effietiveness of remdesivir (RDV) in reducing the rate of of all-cause medically attended visits (MAVs; medical visits attended in person by the participant and a health care professional) or death in non-hospitalized participants with early stage coronavirus disease 2019 (COVID-19) and to evaluate the safety of RDV administered in an outpatient setting.

8. Cancer Distress Management Program for Liver and Biliary Cancer within a SPORE

   Rochester, Minn.

   The aim of this study is to develop a feasible, acceptable, and sustainable comprehensive cancer distress management program that is tailored to the unique needs of cancer patient survivors.

    

9. TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study)

   Jacksonville, Fla.

   The purpose of this study is to characterize TRPC6 risk variants for doxorubicin-related cardiotoxicity in prospectively collected samples from breast cancer patients.   

   Breast cancer patients are more than three times at risk for developing congestive heart failure (CHF), compared with patients who did not have cancer. The increased risk of HF is observed as early as one year from diagnosis of cancer and overall, 7% of patients develop CHF (median follow-up 8.5 years) 

10. Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

    Rochester, Minn.

    The purpose of this study is to develop a blood test to distinguish various causes of diabetes by evaluating patients who have developed diabetes within the last 3 years, but we will also enroll a small number of patients with long-term diabetes and normal blood sugars for comparison. 

    Diabetes mellitus is a common condition which is defined by persistently high blood sugar levels.  This is a frequent problem that is most commonly due to type 2 diabetes.  However, it is now recognized that a small portion of the population with diabetes have an underlying problem with their pancreas, such as chronic pancreatitis or pancreatic cancer, as the cause of their diabetes.  Currently, there is no test to identify the small number of patients who have diabetes caused by a primary problem with their pancreas.